Research programme: nicotinamide phosphoribosyltransferase inhibitors - MyrexisAlternative Names: Cancer metabolism inhibitor programme; CMI programme; MPC-8640; MPC-9528; MPI-0486348; MPI-486348
Latest Information Update: 26 Nov 2012
At a glance
- Originator Myriad Pharmaceuticals
- Developer Myrexis
- Class Small molecules
- Mechanism of Action Nicotinamide phosphoribosyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- Available For Licensing Yes
Highest Development Phases
- Suspended Cancer